Document is current
Any future updates will be listed below
-
Authors
Dyson, Zoe A.
Cerdeira, Louise
Sharma, Vandana
Carey, Megan E.
Holt, Kathryn E.
,
Aanensen, David M.
Abbas, Ali H.
Fayad, Antoine Abou
Afolayan, Ayorinde O.
Ahmed, Niyaz
Ahmed, Irshad
Amir, Afreenish
Andleeb, Saadia
Argimón, Silvia
Aseffa, Abraham
Ashton, Philip M.
Aworh, Mabel K.
Bavdekar, Ashish R.
Chattaway, Marie A.
Chew, Ka Lip
Crump, John A.
Darton, Thomas C.
Diaz, Paula L.
Dolecek, Christiane
Feasey, Nicholas A.
Greenhill, Andrew R.
Gupta, Madhu
Hatta, Mochammad
Hendriksen, Rene S.
Heyderman, Robert S.
Ikhimiukor, Odion O.
Ikram, Aamer
Ingle, Danielle J.
Kapil, Arti
Keane, Jacqueline A.
Keddy, Karen H.
Kingsley, Robert A.
Levine, Myron M.
MacLennan, Calman A.
Maes, Mailis
Mahindroo, Jaspreet
Mashe, Tapfumanei
Morita, Masatomo
Mylona, Elli
Nagaraj, Geetha
Nair, Satheesh
Naseri, Take K.
Njamkepo, Elisabeth
Octavia, Sophie
Okeke, Iruka N.
Owusu, Michael
de la Gandara, Maria Pardos
Pollard, Andrew J.
Rahman, Sadia I. A.
Rahman, Saikt
Rasko, David A.
Redwan, Elrashdy M.
Rokney, Assaf
Rupali, Priscilla
Rutanga, Jean Pierre
Shakya, Jivan
Saha, Senjuti
Sikorski, Michael J.
Smith, Anthony M.
Tagg, Kaitlin A.
Taneja, Neelam
Tamrakar, Dipesh
Turner, Paul
Ussher, James E.
Van Puyvelde, Sandra
Vandelannoote, Koen
Weill, François-Xavier
Wong, Vanessa K.
Wright, Jackie
-
Funding
Funding for this research was provided by:
Wellcome Trust (219692/Z/19/Z & 226432/Z/22/Z, 219692/Z/19/Z & 226432/Z/22/Z, 219692/Z/19/Z & 226432/Z/22/Z, 219692/Z/19/Z & 226432/Z/22/Z, 219692/Z/19/Z & 226432/Z/22/Z, 219692/Z/19/Z & 226432/Z/22/Z)
Horizon 2020 Framework Programme (845681, 845681)
- License Information
-
More Information
Article History
Received: 14 June 2024
Accepted: 8 April 2025
First Online: 9 May 2025
Declarations
:
: Not applicable as the project concerns only data which are already in the public domain (please see Availability of data and materials), and no personal or clinical information relating to the bacterial isolates is included.
: Not applicable.
: KLC has received consultancy payments from Pfizer, travel support from BD, and is a member of the Society for Infectious Disease (Singapore). Robert SH was a chair for a Phase I/II/III studies to determine efficacy, safety and immunogenicity of the candidate Coronavirus Disease (COVID- 19) vaccine ChAdOx1 nCoV- 19, and a chair for a Phase 1 Clinical Study to Determine the Safety and Immunogenicity of a Novel GMMA Vaccine Against Invasive Non-Typhoid Salmonella. Robert SH is also an executive board member of the International Society of Infectious Diseases, a member of the Infection & Immunity Board for the MRC/UKRI, and a member of the NIHR Global Health Research Professorships Committee. MML was a co-developer of a Trivalent Salmonella (Enteritidis/Typhimurium/Typhi Vi) conjugate vaccine with Bharat Biotech International and the Wellcome Trust. MML has also received payments from Pfizer for consultancy work. MML holds US patents for “Compositions and Methods for Producing Bacterial Conjugate Vaccines”. MML was a member of a NIH DSMB that oversaw US government-funded efficacy trials of COVID- 19 vaccines. DSMB was disbanded after several vaccines were given Emergency Use Authorization. MML was a member of the Vaccines and Related Biological Products Advisory Committee of the FDA. CAM holds a patent for Salmonella conjugate vaccines and was an employee of Novartis Vaccines Institute for Global Health. INO has received payments from the Wellcome Trust for consultancy work (review panel member). INO receives royalties for books or book chapters published via Springer, Cornell University Press, and Oxford University Press. INO has received travel support from BMGF, ESCMID, and the American ASM. INFO has held leadership or advisory roles for Wellcome SEDRIC, the BMGF surveillance advisory group, the Thomas Bassir Biomedical Foundation, and International Centre for Antimicrobial Resistance Solutions (ICARS) Technical Advisory Forum. INO has also been the surveillance lead for the AMR Technical Work Group, Nigeria Center for Disease Control, the commissioner for The Lancet Commission for Nigeria, a scientific advisor for The Lancet Infectious Diseases, a senior editor for Microbial Genomics, and the editor in chief of the African Journal of Laboratory Medicine. AJP has been involved an Oxford University partnership with AZ for development of COVI19 vaccines. AJP has received payments for consultancy work from Shionogi. AJP is chair of DHSC’s Joint Committee on Vaccination and Immunisation, and was a member of WHOs SAGE. MAC received support for travel from UKHSA, HEE and NIHR. JAC received support from BMGF, US NIH, and the WHO. NAF holds an NIHR Global Health Professorship. ARG received support from BMGF. The remaining authors declare no competing interests.
